Timed-Sequential Induction in CBF-AML

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Chemotherapy (DAUNORUBICINE-CYTARABINE)

A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)

DRUG

Chemotherapy (DAUNORUBICINE-CYTARABINE)

Chemotherapy induction sequential

Trial Locations (1)

30029

Service Hematologie Oncologie, Nîmes

All Listed Sponsors
collaborator

Acute Leukemia French Association

OTHER

collaborator

French Innovative Leukemia Organisation

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT00428558 - Timed-Sequential Induction in CBF-AML | Biotech Hunter | Biotech Hunter